摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(1S,2R,3R)-3-(hydroxymethyl)-cyclopentane-1,2-diol acetonide | 864683-20-5

中文名称
——
中文别名
——
英文名称
(1S,2R,3R)-3-(hydroxymethyl)-cyclopentane-1,2-diol acetonide
英文别名
[(3aR,4R,6aS)-2,2-dimethyl-4,5,6,6a-tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]methanol
(1S,2R,3R)-3-(hydroxymethyl)-cyclopentane-1,2-diol acetonide化学式
CAS
864683-20-5
化学式
C9H16O3
mdl
——
分子量
172.224
InChiKey
JEKXDBJKESFWRL-GJMOJQLCSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.6
  • 重原子数:
    12
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    38.7
  • 氢给体数:
    1
  • 氢受体数:
    3

反应信息

  • 作为反应物:
    描述:
    (1S,2R,3R)-3-(hydroxymethyl)-cyclopentane-1,2-diol acetonide吡啶二溴三苯基膦 作用下, 以 二氯甲烷 为溶剂, 反应 730.5h, 生成 [(3aR,4S,6aS)-2,2-dimethyl-4,5,6,6a-tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]methyl-[(3S)-4-methoxy-4-oxo-3-(phenylmethoxycarbonylamino)butyl]phosphinic acid
    参考文献:
    名称:
    对应于谷氨酰胺-γ-谷氨酸的膦酸磷酸肽的立体选择性合成及其掺入有效的多聚-γ-谷氨酰合成酶抑制剂
    摘要:
    将H 3 PO 2自由基加到N- / C-保护的乙烯基甘氨酸中可得到相应的H-次膦酸,产率极高。将非亲核性H-次膦酸转化为亲核性的P III物种RP(OTMS)2,该物质以两种方法用于含有伪肽的目标次膦酸。开发了一种新的方法,可导致RP(OTMS)2与未活化的亲电试剂(包括无环均烯丙基溴)的反应获得优异的收率。然而,途中目标假肽,RP(OTMS)的阿尔布蜀夫反应2与环状高烯丙基溴,(ř)-3-(溴甲基)-环戊-1-烯导致重排的烯丙基次膦酸而不是所需的均烯丙基衍生物,即假定的谷氨酸替代物。将RP(OTMS)2共轭添加到含有手性助剂的α-亚甲基戊二酸酯中只会导致适度的非对映选择性。通过快速色谱纯化提供假肽的两种非对映异构体的保护衍生物。整体脱保护后,(S)-H-Glu-γ-[Ψ(P(O)(OH)(CH 2))]-(S)-Glu-OH与(S)-H-Glu-γ偶联-[Ψ(P(O)(OH)(CH 2
    DOI:
    10.1021/jo0507439
  • 作为产物:
    描述:
    (S)-(-)-3-(hydroxymethyl)-cyclopent-1-ene 在 palladium hydroxide - carbon 吡啶sodium periodate四氧化锇氢气对甲苯磺酸 作用下, 以 乙醇 、 various solvents 、 丙酮 为溶剂, 20.0 ℃ 、275.79 kPa 条件下, 反应 32.25h, 生成 (1S,2R,3R)-3-(hydroxymethyl)-cyclopentane-1,2-diol acetonide
    参考文献:
    名称:
    对应于谷氨酰胺-γ-谷氨酸的膦酸磷酸肽的立体选择性合成及其掺入有效的多聚-γ-谷氨酰合成酶抑制剂
    摘要:
    将H 3 PO 2自由基加到N- / C-保护的乙烯基甘氨酸中可得到相应的H-次膦酸,产率极高。将非亲核性H-次膦酸转化为亲核性的P III物种RP(OTMS)2,该物质以两种方法用于含有伪肽的目标次膦酸。开发了一种新的方法,可导致RP(OTMS)2与未活化的亲电试剂(包括无环均烯丙基溴)的反应获得优异的收率。然而,途中目标假肽,RP(OTMS)的阿尔布蜀夫反应2与环状高烯丙基溴,(ř)-3-(溴甲基)-环戊-1-烯导致重排的烯丙基次膦酸而不是所需的均烯丙基衍生物,即假定的谷氨酸替代物。将RP(OTMS)2共轭添加到含有手性助剂的α-亚甲基戊二酸酯中只会导致适度的非对映选择性。通过快速色谱纯化提供假肽的两种非对映异构体的保护衍生物。整体脱保护后,(S)-H-Glu-γ-[Ψ(P(O)(OH)(CH 2))]-(S)-Glu-OH与(S)-H-Glu-γ偶联-[Ψ(P(O)(OH)(CH 2
    DOI:
    10.1021/jo0507439
点击查看最新优质反应信息

文献信息

  • Synthesis of Isopeptide Epoxide Peptidomimetics
    作者:Debatosh Majumdar、Matthew D. Alexander、James K. Coward
    DOI:10.1021/jo801907p
    日期:2009.1.16
    Two epoxide-containing peptidomimetics of the isopeptide, glutatnyl-gamma-glutamate, have been synthesized via a route that should be generally applicable to the synthesis of isopeptide analogues in which an oxirane replaces the scissile peptide bond. Enzymes that catalyze the hydrolysis of peptides and isopeptides are often susceptible to inactivation by electrophilic substrate analogues. In this research, an epoxide was installed as an electrophilic replacement of the scissile isopeptide bond. The C-terminal glutamyl mimic was accessed by the stereospecific synthesis of suitably substituted cyclopentenes, 8 and 10, as surrogates for either the L- or D- enantiomer. The enantiomeric cyclopentenes were further elaborated to incorporate an appended sulfone that was reacted with a suitably protected glutamyl-gamma-semialdehyde in a Julia-Kocienski olefination reaction. This olefination afforded predominantly the desired E-olefin isosteres of L-glutamyl-gamma-D-glutamate and L-glutamyl-gamma-L-glutamate, following which peracid-mediated epoxidation and deprotection provided the epoxide-containing peptidomimetics, 4 and 5.
  • Novel Spirobicyclic Analogues
    申请人:Janssen Pharmaceutica NV
    公开号:US20210380627A1
    公开(公告)日:2021-12-09
    The present invention relates to novel spirobicyclic analogues of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as PRMT5 inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.
查看更多